Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma
Abstract The advent of genomics has led to the identification of specific “driver” mutations in oncogenic kinases, and the development of targeted small molecule inhibitors to block their tumor-driving functions. These specific inhibitors have been a clinical success, and often significantly prolong...
Guardado en:
Autores principales: | Dana S. Neel, Trever G. Bivona |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0533102711904302b1f2fc1f1df3168a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Overcoming resistance to BRAFV600E inhibition in melanoma by deciphering and targeting personalized protein network alterations
por: S. Vasudevan, et al.
Publicado: (2021) -
Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting
por: Torsten Tonn, et al.
Publicado: (2021) -
Correction: Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting
Publicado: (2021) -
Hepatoid Adenocarcinoma of the Lung
por: Meihui Li, et al.
Publicado: (2021) -
Construction of a circRNA-miRNA-mRNA Regulated Pathway Involved in EGFR-TKI Lung Adenocarcinoma Resistance
por: Chenyue Dai MM, et al.
Publicado: (2021)